CMS Eyeing Test To Lower Part B Drug Payments Through ASP Formula Change

Agency looks to its innovation center in lieu of legislation to curb spending; new budget plans cites $7.8bn in 10-year savings from rates set at ASP+3%.

The Centers for Medicare and Medicaid Services is considering launching a new payment model experiment later in 2016 that would test lower reimbursement for drugs administered by physicians or in a hospital outpatient setting and covered under Medicare Part B.

The agency’s interest in such a test came to light when a CMS announcement about the program was posted on...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United States

Initial Medicare Price Offer For Ozempic, Wegovy Almost Half Off Net, Analysis Suggests

 
• By 

Only Bausch Health’s Xifaxan may have had a lower initial offer among the 15 drugs in the current Medicare price negotiation round, researchers at the University of Washington and the University of California, San Diego, projected.

Industry Rethinking Visual Elements And Quality-Of-Life Claims After US FDA Drug Ad Crackdown

 
• By 

Sponsors should consider whether their TV commercials contain the same number of scene changes during the major statement as ads that received a violation letter.

Gene Therapy Sponsors Seek More US FDA ‘Platform’ Guidance, Offer Master File Idea

 

One clear message from a US FDA listening session on leveraging knowledge across cell and gene therapy products is sponsors want more guidance on how the FDA’s new platform therapy pathway will function.

Will US FDA’s Missed Hiring Goals Impact Upcoming User Fee Negotiations?

 

The FDA only added 39% of the promised new user fee-related hires in FY 2025 and also missed hiring goals for the previous two fiscal years.

More from North America

Will US FDA’s Missed Hiring Goals Impact Upcoming User Fee Negotiations?

 

The FDA only added 39% of the promised new user fee-related hires in FY 2025 and also missed hiring goals for the previous two fiscal years.

Legal ‘Squishiness,’ DoJ Reorganization Could Shape Ad/Promo Enforcement Strategy

 
• By 

The extent of FDA and Justice Department coordination on recent warning and untitled letters is unclear, but the “squishy” issues cited in many of the letters and recent elimination of DoJ’s Consumer Protection Branch could influence legal action, industry lawyers said.

First Cohort Shows Many Routes To US FDA’s Commissioner’s National Priority Voucher

 

Experts raised concerns about the pilot program's larger than expected size and the lack of transparency about the reasons the cohort deserved vouchers over a pool that the FDA said included hundreds of candidates.